BERLIN-CHEMIE: 45 years of inclusion and success of people with disabilities with the Social Enterprise Department

BERLIN-CHEMIE: 45 years of inclusion and success of people with disabilities with the Social Enterprise Department

Berlin-Adlershof, 01/12/2023 – BERLIN-CHEMIE, a global drugmaker headquartered in Berlin-Adlershof, is not only celebrating this year's International Day of Persons with Disabilities on 3rd December but also the proud 45th anniversary of its groundbreaking Social Enterprise Department. This anniversary marks a significant milestone in the company's history and sends out a clear signal for equality and inclusion of people with disabilities in society and in industry.

Since it was brought into being in 1978, BERLIN-CHEMIE's Social Enterprise Department has made an outstanding contribution to the integration of what are now around 30 staff with mental and in some cases physical disabilities. As a firm fixture at the LAGeSo-certified pharmaceutical concern with a GDR history, it has established itself over the years as an integral part of the company's pharmaceutical manufacturing, and this has not just national but international significance as well.

"People's wellbeing and welfare are two values that underpin our philosophy as part of the MENARINI Group," stresses Dr. Christian Matschke, Member of the BERLIN-CHEMIE Executive Board and responsible for manufacturing. "Our Social Enterprise Department is a centrepiece of our site in Adlershof and something that the workforce as a whole benefits from. This year's 45th anniversary is a retrospective of the department's successful history – and equally a view to a future in which we'd like to carry on doing our bit to promote the integration of people with disabilities in the public realm and on the employment market."

The Social Enterprise Department extends over an area of about 1,000 m² in a modern production building and is run by an eight-strong leadership team including carers specially trained for the task. A diverse range of pharmaceutical tasks are covered here, among them the manual finishing and reworking of primarily packaged medicinal products, the replacement of package leaflets, folding, bundling and the attachment of labels, right up to the processing of training materials and dealing with company mail. An impressive 3.9 million package units were handled in the Year 2022, and the trend is a rising one.

The department's success is based on a collaborative approach, which is characterised by appreciation and teamwork. Sebastian Jastram, Head of the Social Enterprise Department, stresses: "We work together as a unit and always pay attention to treating each other with respect when doing so. Through constant process optimisations, we achieve a virtually error-free way of operating and at the same time create a motivating working atmosphere that's characterised by a desire to get things done."

Despite the positive results of the Germany-wide unique and sustainable initiative, which has already been recognised by the German Association of the Chemical Industry (VCI) with the 2018 Responsible Care Prize, the skills shortage is also making itself felt in the Social Enterprise Department. In order to continue to set a positive example for successful inclusion in the future as well, it is therefore a particular concern of BERLIN-CHEMIE to create more visibility and to show that potential and room for new perspectives exist within the pharmaceutical industry.



BERLIN-CHEMIE AG is an international, research-based pharmaceutical company with its head office in Berlin, Germany. The company is a subsidiary of the Italian pharmaceutical and diagnostics company MENARINI and is responsible within the group for the German, central and eastern European and central Asian markets. In the Year 2022, BERLIN-CHEMIE was employing around 5,000 staff worldwide and brought in sales of 1.5 billion euro.


About the MENARINI Group

The MENARINI Group, headquartered in Florence, Italy, is represented in over 140 countries worldwide and generated turnover of 4.155 billion euro in 2022. For more than 135 years, MENARINI has been investing in the development and commercial distribution of medicines to offer patients and healthcare professionals all over the world a broad product portfolio in areas including cardiovascular, respiratory, gastroenterology, metabolism, infectious diseases and anti-inflammatory/pain-relieving therapies. MENARINI is also strongly committed to the field of oncology.


Press contact:

Alessandro Grua
Manager Communication & Public Relations

+49 30 6707-3010